Taysha Gene Therapies (TSHA) Interest Coverage Ratio (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Interest Coverage Ratio of 0.76 for Q1 2026, up 99.97% sequentially from 2358.33 in Q4 2025, and up 69.84% YoY from 0.45 in Q1 2025.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Interest Coverage Ratio for 7 years, with the latest figure at 0.76 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 69.84% year-over-year to 0.76 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.32 (up 77.76% YoY) and the FY2025 annual result came in at 1.35, down 68.82% from the prior year.
- Interest Coverage Ratio grew to 0.76 in Q1 2026 per TSHA's latest filing, from 2358.33 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.73 in Q2 2023 and troughed at 2358.33 in Q4 2025.
- A 5-year average of 149.06 and a median of 2.22 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2025: Interest Coverage Ratio jumped 98.38% in 2023, then tumbled 61449.52% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 26.45 in 2022, then jumped by 53.93% to 12.19 in 2023, then jumped by 68.56% to 3.83 in 2024, then sank by 61449.52% to 2358.33 in 2025, then soared by 99.97% to 0.76 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.76, 2358.33, and 1.09 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | -7,891.50 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,891.50 |
| Mar 31, 2026 | -4,831.78 |
| Dec 31, 2025 | -2,358.33 |
| Sep 30, 2025 | -2,268.27 |
| Jun 30, 2025 | -1,573.71 |
| Mar 31, 2025 | -1,127.42 |
| Dec 31, 2024 | -906.00 |
| Sep 30, 2024 | -1,079.08 |
| Jun 30, 2024 | -788.85 |
| Mar 31, 2024 | -838.97 |
| Dec 31, 2023 | -22.79 |
| Sep 30, 2023 | -11.05 |
| Jun 30, 2023 | -16.24 |
| Mar 31, 2023 | -12.05 |
| Dec 31, 2022 | -41.35 |
| Sep 30, 2022 | -23.62 |
| Jun 30, 2022 | -44.92 |
| Mar 31, 2022 | -73.89 |
| Dec 31, 2021 | -71.96 |
| Sep 30, 2021 | -93.34 |